CoChat

Keratinocytes produce IL-17c to protect peripheral nervous systems during human HSV-2 reactivation

Open access

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Abstract

Despite frequent herpes simplex virus (HSV) reactivation, peripheral nerve destruction and sensory anesthesia are rare. We discovered that skin biopsies obtained during asymptomatic human HSV-2 reactivation exhibit a higher density of nerve fibers relative to biopsies during virological and clinical quiescence. We evaluated the effects of HSV infection on keratinocytes, the initial target of HSV replication, to better understand this observation. Keratinocytes produced IL-17c during HSV-2 reactivation, and IL-17RE, an IL-17c-specific receptor, was expressed on nerve fibers in human skin and sensory neurons in dorsal root ganglia. In ex vivo experiments, exogenous human IL-17c provided directional guidance and promoted neurite growth and branching in microfluidic devices. Exogenous murine IL-17c pretreatment reduced apoptosis in HSV-2-infected primary neurons. These results suggest that IL-17c is a neurotrophic cytokine that protects peripheral nerve systems during HSV reactivation. This mechanism could explain the lack of nerve damage from recurrent HSV infection and may provide insight to understanding and treating sensory peripheral neuropathies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1084/jem.20160581

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Nerve fiber growth during HSV-2 reactivation. (A) Nerve fibers in skin biopsies at time of subclinical HSV-2 reactivation (shedding) are stained for NCAM (green). An increased number of NCAM+ nerve fibers in the area just below the dermal epidermal junction, the site of HSV-2 reactivation, is seen as compared with control biopsy obtained from contralateral genital skin. Cells were costained with an anti-CD8a antibody (yellow) and DAPI (blue). Bar, 100 µm. (B) Comparison of length and width of NCAM+ nerve fibers among biopsies obtained at time of HSV-2 lesion (Lesion), 4 and 8 wk posthealed (4/8 wph), contralateral control biopsies (Gen ctrl), and arm control biopsies (Arm ctrl; n = 10). *, P = 0.043; **, P = 0.031. P-values are derived from paired two-sample t tests. (C) NCAM+ nerve fibers express NGFR and intermediate filaments (peripherin and NF200). Tissue of 4 wk posthealed asymptomatic shedding skin biopsies was double stained with anti-NCAM (green) and NGFR (red), peripherin (red) or NF200 (red) antibodies. Bar, 50 µm.
Figure 1. Nerve fiber growth during HSV-2 reactivation. (A) Nerve fibers in skin biopsies at time of subclinical HSV-2 reactivation (shedding) are stained for NCAM (green). An increased number of NCAM+ nerve fibers in the area just below the dermal epidermal junction, the site of HSV-2 reactivation, is seen as compared with control biopsy obtained from contralateral genital skin. Cells were costained with an anti-CD8a antibody (yellow) and DAPI (blue). Bar, 100 µm. (B) Comparison of length and width of NCAM+ nerve fibers among biopsies obtained at time of HSV-2 lesion (Lesion), 4 and 8 wk posthealed (4/8 wph), contralateral control biopsies (Gen ctrl), and arm control biopsies (Arm ctrl; n = 10). *, P = 0.043; **, P = 0.031. P-values are derived from paired two-sample t tests. (C) NCAM+ nerve fibers express NGFR and intermediate filaments (peripherin and NF200). Tissue of 4 wk posthealed asymptomatic shedding skin biopsies was double stained with anti-NCAM (green) and NGFR (red), peripherin (red) or NF200 (red) antibodies. Bar, 50 µm.CC BY-NC-SA · PubMed Central
Figure 2. Recurrent HSV-2 infection induces IL-17c expression in keratinocytes. (A) Isolation of keratinocytes above basement membrane by LCM. (B) Expression of keratin 5 (KRT5) and 14 (KRT14), CD1a and CD8a in laser-captured keratinocytes (kera), CD1a+ Langerhans cells (LC), and CD8a+ CD8 T cells (CD8) from control (ctrl) and posthealed (PH) genital skin biopsies during recurrent HSV-2 infection. Y-axis, intensity values from normalized Illumina bead array data. The displayed values are the means for keratinocytes (n = 4), CD1a+ Langerhans cells (n = 8), and CD8a+ CD8 T cells (n = 8). 1, kera_ctrl; 2, kera_PH; 3, CD8_ctrl; 4, CD8_PH; 5, LC_ctrl; and 6, LC_PH. (C) HSV infection in keratinocytes induced IL-17c expression in vivo. Comparison of expression of cytokines/chemokines (top) and six different members of IL-17 (bottom) in keratinocytes isolated from lesion and posthealed skin (asymptomatic shedding) biopsies to those from contralateral control biopsies. (D) IL-17c protein expression in epidermal keratinocytes in skin biopsies during lesion and shedding (clinical quiescence 8-wk shedding). IL-17c expression was detected by immunofluorescent staining with an anti-IL-17c antibody (green) and nuclei stained with DAPI (blue). Bar, 50 µm.
Figure 2. Recurrent HSV-2 infection induces IL-17c expression in keratinocytes. (A) Isolation of keratinocytes above basement membrane by LCM. (B) Expression of keratin 5 (KRT5) and 14 (KRT14), CD1a and CD8a in laser-captured keratinocytes (kera), CD1a+ Langerhans cells (LC), and CD8a+ CD8 T cells (CD8) from control (ctrl) and posthealed (PH) genital skin biopsies during recurrent HSV-2 infection. Y-axis, intensity values from normalized Illumina bead array data. The displayed values are the means for keratinocytes (n = 4), CD1a+ Langerhans cells (n = 8), and CD8a+ CD8 T cells (n = 8). 1, kera_ctrl; 2, kera_PH; 3, CD8_ctrl; 4, CD8_PH; 5, LC_ctrl; and 6, LC_PH. (C) HSV infection in keratinocytes induced IL-17c expression in vivo. Comparison of expression of cytokines/chemokines (top) and six different members of IL-17 (bottom) in keratinocytes isolated from lesion and posthealed skin (asymptomatic shedding) biopsies to those from contralateral control biopsies. (D) IL-17c protein expression in epidermal keratinocytes in skin biopsies during lesion and shedding (clinical quiescence 8-wk shedding). IL-17c expression was detected by immunofluorescent staining with an anti-IL-17c antibody (green) and nuclei stained with DAPI (blue). Bar, 50 µm.CC BY-NC-SA · PubMed Central
Figure 3. HSV-2 infection in human primary keratinocytes induces IL-17c, which does not appear to have significant antiviral effect. (A) IL-17c expression in HSV infected human primary keratinocytes. IL-17c RNA expression in a time course of HSV-2-infected keratinocytes (left). Cells were mock infected (aqua) or infected with HSV-2 (HG52; MOI = 1) in the absence (blue) or presence (green) of acyclovir (30 µM) or with UV-inactivated viruses (red). Purple is acyclovir without virus. Y-axis is fold change of RNA levels above mock infected cells; x-axis is time after infection in hours. HSV-2 virus growth curve in primary keratinocytes was determined by plaque assay (middle). Y-axis is PFU (plaque forming units) per million cells; x-axis is time post-infection (hours) of HSV-2 in the absence (blue) or presence (green) of acyclovir or UV-inactivated viruses (red). IL-17c expression in a time course of HSV-1-infected human primary keratinocytes (right). Cells were mock infected or infected with HSV-1 (KOS; MOI of 1). (B) IL-17c protein expression in HSV-2-infected keratinocytes. Cells mock (bottom) or HSV-2 infected (top) for 7 h at MOIs of 1 and 10 were analyzed for IL-17c expression by immunofluorescent staining with an anti–IL-17c antibody (red). Nuclei stained with DAPI (blue). Graph is quantification of staining as the percentage of IL-17c-expressing cells. M, mock; 1, MOI of 1; 10, MOI of 10. Bar, 50 µm. (C and D) HSV-2 and TLR ligands additively induced IL-17c expression in human primary keratinocytes. Cells were treated with TLR ligands (PGN, poly[I:C]/LyoVec, poly[I:C], LPS, flagellin, and ODN) for 2, 6, and 24 h (C) or infected with HSV-2 for 3 h and then treated with poly[I:C]/LyoVec, poly[I:C], or flagellin for another 4 h (D). Y-axis, IL-17c RNA expression fold changes relative to untreated and mock infected controls. (E) Blocking IL-17c signaling does not have significant effect on HSV-2 gene expression or viral titers in infected human primary keratinocytes. Cells were pretreated with an IL-17RA neutralizing antibody (red) or matching control IgG (blue) for 1 h before HSV-2 infection. Gene expression (ICP27) was assayed by quantitative PCR (left), and viral titers were determined by plaque assay in Vero cells (right). Error bars represent 1 standard deviation from the mean of three replicates. All the experiments were repeated three times.
Figure 3. HSV-2 infection in human primary keratinocytes induces IL-17c, which does not appear to have significant antiviral effect. (A) IL-17c expression in HSV infected human primary keratinocytes. IL-17c RNA expression in a time course of HSV-2-infected keratinocytes (left). Cells were mock infected (aqua) or infected with HSV-2 (HG52; MOI = 1) in the absence (blue) or presence (green) of acyclovir (30 µM) or with UV-inactivated viruses (red). Purple is acyclovir without virus. Y-axis is fold change of RNA levels above mock infected cells; x-axis is time after infection in hours. HSV-2 virus growth curve in primary keratinocytes was determined by plaque assay (middle). Y-axis is PFU (plaque forming units) per million cells; x-axis is time post-infection (hours) of HSV-2 in the absence (blue) or presence (green) of acyclovir or UV-inactivated viruses (red). IL-17c expression in a time course of HSV-1-infected human primary keratinocytes (right). Cells were mock infected or infected with HSV-1 (KOS; MOI of 1). (B) IL-17c protein expression in HSV-2-infected keratinocytes. Cells mock (bottom) or HSV-2 infected (top) for 7 h at MOIs of 1 and 10 were analyzed for IL-17c expression by immunofluorescent staining with an anti–IL-17c antibody (red). Nuclei stained with DAPI (blue). Graph is quantification of staining as the percentage of IL-17c-expressing cells. M, mock; 1, MOI of 1; 10, MOI of 10. Bar, 50 µm. (C and D) HSV-2 and TLR ligands additively induced IL-17c expression in human primary keratinocytes. Cells were treated with TLR ligands (PGN, poly[I:C]/LyoVec, poly[I:C], LPS, flagellin, and ODN) for 2, 6, and 24 h (C) or infected with HSV-2 for 3 h and then treated with poly[I:C]/LyoVec, poly[I:C], or flagellin for another 4 h (D). Y-axis, IL-17c RNA expression fold changes relative to untreated and mock infected controls. (E) Blocking IL-17c signaling does not have significant effect on HSV-2 gene expression or viral titers in infected human primary keratinocytes. Cells were pretreated with an IL-17RA neutralizing antibody (red) or matching control IgG (blue) for 1 h before HSV-2 infection. Gene expression (ICP27) was assayed by quantitative PCR (left), and viral titers were determined by plaque assay in Vero cells (right). Error bars represent 1 standard deviation from the mean of three replicates. All the experiments were repeated three times.CC BY-NC-SA · PubMed Central
Figure 4. Peripheral nervous systems express IL-17RE, a receptor subunit specific for IL-17c. (A) Nerve endings in lesional genital skin expressed IL-17RE. IL-17RE+ cells exhibited elongated fiber-like shapes and were distinct from CD15+, CD8a+, and CD4+ cells. Double immunofluorescent staining with anti-IL-17RE (red) and anti-CD15, CD8a or CD4 (green) antibodies revealed no costaining (left). Double immunofluorescent staining with anti-NCAM (green) and anti-IL-17RE (red) antibodies showed significant double staining of nerve endings in lesional biopsies (right). Nuclei stained with DAPI (blue). Bar, 50 µm. (B) Nerve endings in control skin biopsies express IL-17RE and IL-17RA. Double staining with anti-NCAM and anti-IL17RE or IL-17RA antibody showed double-positive nerve endings in control skin biopsies. Bar, 50 µm. (C) Nerve endings in posthealed skin biopsies express IL-17RE and IL-17RA. Double immunofluorescent staining with anti-peripherin (green) and anti-IL-17RE (red) antibodies (left) or anti-NCAM (green) and anti-IL17RA (red) antibodies (right) revealed expression of IL-17RE on peripherin+ nerve endings and expression of IL-17RA on NCAM+ nerve endings in genital 4-wk posthealed skin biopsies. Nuclei stained with DAPI (blue). Bar, 50 µm. (D) Single immunofluorescent staining with anti-IL-17RE (red) in sensory neurons from human fetal DRG showed staining in both neuronal cell bodies and nerve fibers. Insets show enlarged pictures of IL-17RE expression in cell bodies (top) and axons (bottom). Bar, 500 µm. (E) Detection of IL-17RE RNA expression in sensory neurons in human fetal DRG using FISH. TUBB3, tubulin β 3 class III. Three representative images are displayed. Bars, 50 µm. (F) IL-17RE (red) expression in a subset of NF200+ (left; green) or peripherin+ neurons (right; green) and axons in human fetal DRG. Bar, 50 µm. All the experiments were repeated three times.
Figure 4. Peripheral nervous systems express IL-17RE, a receptor subunit specific for IL-17c. (A) Nerve endings in lesional genital skin expressed IL-17RE. IL-17RE+ cells exhibited elongated fiber-like shapes and were distinct from CD15+, CD8a+, and CD4+ cells. Double immunofluorescent staining with anti-IL-17RE (red) and anti-CD15, CD8a or CD4 (green) antibodies revealed no costaining (left). Double immunofluorescent staining with anti-NCAM (green) and anti-IL-17RE (red) antibodies showed significant double staining of nerve endings in lesional biopsies (right). Nuclei stained with DAPI (blue). Bar, 50 µm. (B) Nerve endings in control skin biopsies express IL-17RE and IL-17RA. Double staining with anti-NCAM and anti-IL17RE or IL-17RA antibody showed double-positive nerve endings in control skin biopsies. Bar, 50 µm. (C) Nerve endings in posthealed skin biopsies express IL-17RE and IL-17RA. Double immunofluorescent staining with anti-peripherin (green) and anti-IL-17RE (red) antibodies (left) or anti-NCAM (green) and anti-IL17RA (red) antibodies (right) revealed expression of IL-17RE on peripherin+ nerve endings and expression of IL-17RA on NCAM+ nerve endings in genital 4-wk posthealed skin biopsies. Nuclei stained with DAPI (blue). Bar, 50 µm. (D) Single immunofluorescent staining with anti-IL-17RE (red) in sensory neurons from human fetal DRG showed staining in both neuronal cell bodies and nerve fibers. Insets show enlarged pictures of IL-17RE expression in cell bodies (top) and axons (bottom). Bar, 500 µm. (E) Detection of IL-17RE RNA expression in sensory neurons in human fetal DRG using FISH. TUBB3, tubulin β 3 class III. Three representative images are displayed. Bars, 50 µm. (F) IL-17RE (red) expression in a subset of NF200+ (left; green) or peripherin+ neurons (right; green) and axons in human fetal DRG. Bar, 50 µm. All the experiments were repeated three times.CC BY-NC-SA · PubMed Central
Figure 5. IL-17c stimulated neurite growth of differentiated SY5Y neurons. (A) IL-17c induced directional neurite growth of differentiated SY5Y cells in a microfluidic device. SY5Y cells were differentiated with all-trans retinoid acids (ATRA) at 20 µg/ml for 4 d and then placed in the wells on the left side of a microfluidic device with culture medium alone (M) or medium plus IL-17c, NGF, or BDNF with or without neutralizing antibodies for IL-17RA (α-IL17RA), NGF (α-NGF), or BDNF (α-BDNF), respectively, on the other side. After 10 d of culture, cells were fixed and stained with a PGP9.5 antibody. Bar, 200 μm. (B) Comparison of total length of neurites and numbers of neurites from all the conditions shown in A. P-value is derived from two-sample t test with unequal variance (n = 3). *, P = 0.047; **, P = 0.036. Error bars represent 1 standard deviation from the mean of three replicates. (C) Size-exclusion chromatogram (SEC) showing an overlay of the soluble forms of human IL-17c (residues 19–197), human IL-17RE (residues 155–451), and human IL-17RA (residues 33–317). Each construct runs as a well-behaved, monodispersed protein of appropriate molecular weight. Gel inset shows a fraction corresponding to each peak analyzed under nonreducing, SDS-PAGE conditions (top). SEC supershift assay showing that recombinant human IL-17c interacts both as ternary complex with IL-17RA and IL-17RE and as a binary complex with IL-17RE alone. Gel inset shows a fraction corresponding to each peak analyzed under nonreducing, SDS-PAGE conditions (bottom). All the experiments were repeated three times.
Figure 5. IL-17c stimulated neurite growth of differentiated SY5Y neurons. (A) IL-17c induced directional neurite growth of differentiated SY5Y cells in a microfluidic device. SY5Y cells were differentiated with all-trans retinoid acids (ATRA) at 20 µg/ml for 4 d and then placed in the wells on the left side of a microfluidic device with culture medium alone (M) or medium plus IL-17c, NGF, or BDNF with or without neutralizing antibodies for IL-17RA (α-IL17RA), NGF (α-NGF), or BDNF (α-BDNF), respectively, on the other side. After 10 d of culture, cells were fixed and stained with a PGP9.5 antibody. Bar, 200 μm. (B) Comparison of total length of neurites and numbers of neurites from all the conditions shown in A. P-value is derived from two-sample t test with unequal variance (n = 3). *, P = 0.047; **, P = 0.036. Error bars represent 1 standard deviation from the mean of three replicates. (C) Size-exclusion chromatogram (SEC) showing an overlay of the soluble forms of human IL-17c (residues 19–197), human IL-17RE (residues 155–451), and human IL-17RA (residues 33–317). Each construct runs as a well-behaved, monodispersed protein of appropriate molecular weight. Gel inset shows a fraction corresponding to each peak analyzed under nonreducing, SDS-PAGE conditions (top). SEC supershift assay showing that recombinant human IL-17c interacts both as ternary complex with IL-17RA and IL-17RE and as a binary complex with IL-17RE alone. Gel inset shows a fraction corresponding to each peak analyzed under nonreducing, SDS-PAGE conditions (bottom). All the experiments were repeated three times.CC BY-NC-SA · PubMed Central
Figure 6. IL-17c induced neurite growth and branch points in HSNs. HSNs were isolated from fetal spinal tissue and cultured in full neural medium only or medium plus IL-17c or NGF. (A) Images of cultured HSNs in the presence of IL-17c at 75 h (top) and 90 h (bottom) after plating. Bar, 300 μm. (B) Live imaging of HSNs to measure neurite length (left graph), neurite branch points (middle graph), and cell body area (right graph) every hour for 16 h from hours 75 to 90 after HSNs were plated in culture medium or medium plus IL-17c or NGF. (C) Growth rates of neurite length (left graph), neurite branch points (middle graph), and cell body area (right graph) of cultured HSNs from hours 75 to 90 after HSNs were plated. (D) A microfluidic device with three channels. HSNs were placed in the middle channel and medium only (M) and medium plus IL-17c was placed on the left and right channels, respectively. DRG, dorsal root ganglia. (E and F) HSNs extended significantly longer neurites with more branch points into the channel with IL-17c containing medium. HSNs were fixed and stained with PGP9.5 after 16 d of culture (E) and number of neurites, total length and branch points were counted (F). Bar, 500 µm. (G and H) The HSN neurites expressed IL-17RE. HSNs in the three-channel device were double-stained with PGP9.5 and IL-17RE antibodies (G). Comparison of growth cones of neurites from medium only and IL-17c-containing channels (H). Bars, 50 μm (H), 10 μm (G). HSN experiments were repeated three times using different fetal DRG.
Figure 6. IL-17c induced neurite growth and branch points in HSNs. HSNs were isolated from fetal spinal tissue and cultured in full neural medium only or medium plus IL-17c or NGF. (A) Images of cultured HSNs in the presence of IL-17c at 75 h (top) and 90 h (bottom) after plating. Bar, 300 μm. (B) Live imaging of HSNs to measure neurite length (left graph), neurite branch points (middle graph), and cell body area (right graph) every hour for 16 h from hours 75 to 90 after HSNs were plated in culture medium or medium plus IL-17c or NGF. (C) Growth rates of neurite length (left graph), neurite branch points (middle graph), and cell body area (right graph) of cultured HSNs from hours 75 to 90 after HSNs were plated. (D) A microfluidic device with three channels. HSNs were placed in the middle channel and medium only (M) and medium plus IL-17c was placed on the left and right channels, respectively. DRG, dorsal root ganglia. (E and F) HSNs extended significantly longer neurites with more branch points into the channel with IL-17c containing medium. HSNs were fixed and stained with PGP9.5 after 16 d of culture (E) and number of neurites, total length and branch points were counted (F). Bar, 500 µm. (G and H) The HSN neurites expressed IL-17RE. HSNs in the three-channel device were double-stained with PGP9.5 and IL-17RE antibodies (G). Comparison of growth cones of neurites from medium only and IL-17c-containing channels (H). Bars, 50 μm (H), 10 μm (G). HSN experiments were repeated three times using different fetal DRG.CC BY-NC-SA · PubMed Central
Figure 7. IL-17c pretreatment reduces apoptosis during HSV-2 infection of MCNs. (A) HSV-2 infection induces expression of IL-17c in MCNs. Cells were infected with HSV-2 (186) at MOI of 5 for 1, 3, 6, 12, 24, and 48 h. Y-axis is fold change over mock infected MCNs. Gene expression (IL-17c and β-actin [ACTB]) was determined by quantitative PCR (top), and virus titers were determined by plaque assays (bottom). (B) Detection by immunofluorescence of cleaved caspase 3 levels in HSV-2 (186) infected MCNs. MCNs were untreated or pretreated with mIL-17c for 24 h in the presence of a murine IL-17RA–neutralizing antibody (anti-mIL17RA) or matching control rat IgG before HSV-2 infection at MOI of 5 for 8 h. Cells were stained with DAPI for cell nucleus, an antibody for β-tubulin III to visualize neurons (green) and an antibody for cleaved caspase 3 (red). Bar, 100 μm. (C) Percentages of cleaved caspase 3+ neurons in HSV-2 (186) infected neurons pretreated with mIL-17c (24 h) in the presence of anti-mIL17RA or control IgG (left) or pretreated with anti-IL-m17RA or control IgG (1 h; right). *, P = 0.01. (D) Detection of caspase 3/7 enzymatic activities in HSV-2 (186) infected MCNs. MCNs were treated and infected similarly as described in B and caspase 3/7 enzymatic activities were assayed by luminescence (relative light unit [RLU]). Error bars represent 1 standard deviation from the mean of three replicates. P-value is derived from two-sample t test with unequal variance. **, P = 0.05. The experiments were repeated three times.
Figure 7. IL-17c pretreatment reduces apoptosis during HSV-2 infection of MCNs. (A) HSV-2 infection induces expression of IL-17c in MCNs. Cells were infected with HSV-2 (186) at MOI of 5 for 1, 3, 6, 12, 24, and 48 h. Y-axis is fold change over mock infected MCNs. Gene expression (IL-17c and β-actin [ACTB]) was determined by quantitative PCR (top), and virus titers were determined by plaque assays (bottom). (B) Detection by immunofluorescence of cleaved caspase 3 levels in HSV-2 (186) infected MCNs. MCNs were untreated or pretreated with mIL-17c for 24 h in the presence of a murine IL-17RA–neutralizing antibody (anti-mIL17RA) or matching control rat IgG before HSV-2 infection at MOI of 5 for 8 h. Cells were stained with DAPI for cell nucleus, an antibody for β-tubulin III to visualize neurons (green) and an antibody for cleaved caspase 3 (red). Bar, 100 μm. (C) Percentages of cleaved caspase 3+ neurons in HSV-2 (186) infected neurons pretreated with mIL-17c (24 h) in the presence of anti-mIL17RA or control IgG (left) or pretreated with anti-IL-m17RA or control IgG (1 h; right). *, P = 0.01. (D) Detection of caspase 3/7 enzymatic activities in HSV-2 (186) infected MCNs. MCNs were treated and infected similarly as described in B and caspase 3/7 enzymatic activities were assayed by luminescence (relative light unit [RLU]). Error bars represent 1 standard deviation from the mean of three replicates. P-value is derived from two-sample t test with unequal variance. **, P = 0.05. The experiments were repeated three times.CC BY-NC-SA · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 39 references

Research works printed but not linked: 1

  1. Chuong, 2002, What is the ‘true’ function of skin?, Exp. Dermatol., 11, 159

Cited by

Metadata

Authors
Peng, T., Chanthaphavong, R. S., Sun, S., Trigilio, J. A., Phasouk, K., Jin, L., Layton, E. D., Li, A. Z., Correnti, C. E., De van der Schueren, W., Vazquez, J., O’Day, D. R., Glass, I. A., Knipe, D. M., Wald, A., Corey, L., & Zhu, J.
Affiliations
  • University of Washington (US)
  • Fred Hutch Cancer Center (US)
  • Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 5
  • Harvard University (US)
Corresponding author
Peng, Tao
Venue
Journal of Experimental Medicine
Published
2017-06-29
Volume
214
Issue
8
Pages
2315-2329
ISSN
  • 0022-1007 (ISSN-L)
  • 1540-9538
OpenAlex
W2732375683
Cited by
60
References
39
Citations by year
2026: 3 · 2025: 6 · 2024: 3 · 2023: 13 · 2022: 7 · 2021: 10 · 2020: 9 · 2019: 6 · 2018: 2 · 2017: 1
FWCI
3.86
Type
journal article
Language
en
Open access
Locations
  • The Journal of Experimental Medicine (publishedVersion, public-domain)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
  • Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
Funders
  • National Institutes of Health (R01 AI042528, R01 AI111780, PO1 AI030731, 5R24HD000836, AI063106)
  • James B. Pendleton Charitable Trust
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development
Topics
  • Health Sciences › Medicine › Infectious Diseases › Herpesvirus Infections and Treatments
  • Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
  • Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
Keywords
IL-17C, HSV-2 reactivation, keratinocytes, sensory neuropathy, IL-17 receptor, dorsal root ganglia, neurite outgrowth, neurotrophic cytokines, neuronal apoptosis, herpes simplex virus, nerve fiber density
MeSH terms
Animals, Herpes Genitalis, Humans, Neuroblastoma, Virus Activation, Keratinocytes, Neurites, Peripheral Nervous System, Herpesvirus 2, Human, Interleukin-17

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.